Patient characteristics for the TT2/TT3 trials
| Factor . | Overall . | TT2 − T . | TT2 + T . | TT3A . | TT3B . | P . |
|---|---|---|---|---|---|---|
| Female sex | 451/1148 (39%) | 135/345 (39%) | 137/323 (42%) | 110/303 (36%) | 69/177 (39%) | .481 |
| Age ≥ 65 y | 266/1148 (23%) | 72/345 (21%) | 64/323 (20%) | 84/303 (28%) | 46/177 (26%) | .061 |
| Albumin < 3.5 g/dL | 275/1143 (24%) | 59/343 (17%) | 60/321 (19%) | 78/303 (26%) | 78/176 (44%) | < .001 |
| B2M ≥ 3.5 mg/L | 478/1145 (42%) | 126/345 (37%) | 117/323 (36%) | 136/303 (45%) | 99/174 (57%) | < .001 |
| LDH ≥ 190 U/L | 328/1145 (29%) | 98/344 (28%) | 106/322 (33%) | 81/303 (27%) | 43/176 (24%) | .175 |
| Cytogenetic abnormalities | 367/1136 (32%) | 104/339 (31%) | 93/322 (29%) | 100/302 (33%) | 70/173 (40%) | .058 |
| GEP70 high-risk | 123/792 (16%) | 20/176 (11%) | 26/175 (15%) | 40/275 (15%) | 37/166 (22%) | .039 |
| GEP80 high-risk | 56/792 (7%) | 6/176 (3%) | 9/175 (5%) | 20/275 (7%) | 21/166 (13%) | .006 |
| Transplantation 1 | 1020/1148 (89%) | 292/345 (85%) | 278/323 (86%) | 285/303 (94%) | 165/177 (93%) | < .001 |
| Transplantation 2 | 834/1148 (73%) | 233/345 (68%) | 213/323 (66%) | 252/303 (83%) | 136/177 (77%) | < .001 |
| Factor . | Overall . | TT2 − T . | TT2 + T . | TT3A . | TT3B . | P . |
|---|---|---|---|---|---|---|
| Female sex | 451/1148 (39%) | 135/345 (39%) | 137/323 (42%) | 110/303 (36%) | 69/177 (39%) | .481 |
| Age ≥ 65 y | 266/1148 (23%) | 72/345 (21%) | 64/323 (20%) | 84/303 (28%) | 46/177 (26%) | .061 |
| Albumin < 3.5 g/dL | 275/1143 (24%) | 59/343 (17%) | 60/321 (19%) | 78/303 (26%) | 78/176 (44%) | < .001 |
| B2M ≥ 3.5 mg/L | 478/1145 (42%) | 126/345 (37%) | 117/323 (36%) | 136/303 (45%) | 99/174 (57%) | < .001 |
| LDH ≥ 190 U/L | 328/1145 (29%) | 98/344 (28%) | 106/322 (33%) | 81/303 (27%) | 43/176 (24%) | .175 |
| Cytogenetic abnormalities | 367/1136 (32%) | 104/339 (31%) | 93/322 (29%) | 100/302 (33%) | 70/173 (40%) | .058 |
| GEP70 high-risk | 123/792 (16%) | 20/176 (11%) | 26/175 (15%) | 40/275 (15%) | 37/166 (22%) | .039 |
| GEP80 high-risk | 56/792 (7%) | 6/176 (3%) | 9/175 (5%) | 20/275 (7%) | 21/166 (13%) | .006 |
| Transplantation 1 | 1020/1148 (89%) | 292/345 (85%) | 278/323 (86%) | 285/303 (94%) | 165/177 (93%) | < .001 |
| Transplantation 2 | 834/1148 (73%) | 233/345 (68%) | 213/323 (66%) | 252/303 (83%) | 136/177 (77%) | < .001 |
Data are shown as n/N, where n indicates the number of patients with the factor and N the number of patients with valid data for the factor.
B2M indicates β-2-microglobulin; LDH, lactate dehydrogenase; and GEP, gene-expression profiling.